These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 21452327

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE.
    Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, Quigg RJ, Holers VM.
    Autoimmunity; 2004 Mar; 37(2):111-23. PubMed ID: 15293881
    [Abstract] [Full Text] [Related]

  • 23. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.
    Chen Z, Koralov SB, Kelsoe G.
    J Exp Med; 2000 Nov 06; 192(9):1339-52. PubMed ID: 11067882
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
    Zhu P, Bailey SR, Lei B, Paulos CM, Atkinson C, Tomlinson S.
    Transplantation; 2017 Apr 06; 101(4):e75-e85. PubMed ID: 28045880
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.
    J Rheumatol; 2002 Apr 06; 29(4):707-16. PubMed ID: 11950011
    [Abstract] [Full Text] [Related]

  • 30. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L, Chen HP, Ma Q.
    Immunol Lett; 2014 Sep 06; 161(1):76-80. PubMed ID: 24837470
    [Abstract] [Full Text] [Related]

  • 31. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt RE, Witte T.
    Ann Rheum Dis; 2008 Feb 06; 67(2):154-61. PubMed ID: 17557887
    [Abstract] [Full Text] [Related]

  • 32. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.
    Bao L, Zhou J, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2003 Oct 06; 14(10):2516-25. PubMed ID: 14514729
    [Abstract] [Full Text] [Related]

  • 33. C1q deficiency and autoimmunity: the effects of genetic background on disease expression.
    Mitchell DA, Pickering MC, Warren J, Fossati-Jimack L, Cortes-Hernandez J, Cook HT, Botto M, Walport MJ.
    J Immunol; 2002 Mar 01; 168(5):2538-43. PubMed ID: 11859149
    [Abstract] [Full Text] [Related]

  • 34. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 35. Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis.
    Elvington M, Schepp-Berglind J, Tomlinson S.
    Clin Exp Immunol; 2015 Mar 15; 179(3):500-8. PubMed ID: 25293413
    [Abstract] [Full Text] [Related]

  • 36. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q, Xiao H, Shi L, He Y, Cai J, Wu J, Li A, Ye L, Yang C, Liu HF.
    Front Immunol; 2020 Mar 15; 11():1047. PubMed ID: 32625200
    [Abstract] [Full Text] [Related]

  • 37. Analysis of C4 and the C4 binding protein in the MRL/lpr mouse.
    Wenderfer SE, Soimo K, Wetsel RA, Braun MC.
    Arthritis Res Ther; 2007 Mar 15; 9(5):R114. PubMed ID: 17971229
    [Abstract] [Full Text] [Related]

  • 38. IL-33 neutralization suppresses lupus disease in lupus-prone mice.
    Li P, Lin W, Zheng X.
    Inflammation; 2014 Jun 15; 37(3):824-32. PubMed ID: 24398614
    [Abstract] [Full Text] [Related]

  • 39. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice.
    Matsumoto K, Watanabe N, Akikusa B, Kurasawa K, Matsumura R, Saito Y, Iwamoto I, Saito T.
    Arthritis Rheum; 2003 Feb 15; 48(2):486-94. PubMed ID: 12571859
    [Abstract] [Full Text] [Related]

  • 40. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC.
    Kidney Int; 2017 Jun 15; 91(6):1386-1397. PubMed ID: 28139294
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.